Literature DB >> 31475093

Validation of molecular biomarkers for preoperative diagnostics of human papillary thyroid carcinoma in fine needle aspirates.

Samira M Sadowski1, Volodymyr Petrenko2,3,4,5, Patrick Meyer2, Marc Pusztaszeri6, Marie-Claude Brulhart-Meynet2,4, Mounia Heddad Masson2,4, Frédéric Triponez1, Jacques Philippe2,4, Charna Dibner2,3,4,5.   

Abstract

BACKGROUND: Despite substantial efforts, reliable preoperative diagnostic for human thyroid malignancies in case of cytologically indeterminate nodules is still missing, resulting in high number of unnecessary thyroidectomies. In an attempt to increase precision of existing preoperative diagnostics, we aimed at validating the panel of molecular biomarkers predictive for papillary thyroid carcinoma (PTC) in preoperative fine needle aspirate (FNA) samples.
METHODS: In this prospective study conducted in preoperative thyroid FNA from 44 thyroid nodules, expression levels of 11 molecular biomarkers previously validated on the postoperative samples of PTCs were measured by Cell-to-CT and QuantiGene Plex methods and correlated with final diagnosis.
RESULTS: The QuantiGene Plex resulted in reliable gene expression measurements for FNA and core-needle biopsy (CNB) samples, however this method was less sensitive than pre-amplification based Cell-to-CT. Measurements conducted on the same samples by the two methods significantly correlated for most of the genes. Expression levels of TIMP1, c-MET and ARNTL were upregulated in PTC nodules as compared to benign counterparts, supporting previous post-operative studies. Strong correlation was observed between these biomarker alterations in the same samples. Within the sub-group of 15 indeterminate nodules (Bethesda II-V), TIMP1 had 100% specificity and 83% sensitivity for PTC cases.
CONCLUSIONS: Assessment of TIMP1, c-MET and core-clock gene ARNTL expression levels by QuantiGene Plex assay in FNA samples holds promise as an ancillary method to the cytological preoperative diagnostics.

Entities:  

Keywords:  Papillary thyroid cancer (PTC); biomarkers; fine needle aspirates (FNAs); preoperative diagnostics

Year:  2019        PMID: 31475093      PMCID: PMC6694023          DOI: 10.21037/gs.2018.11.04

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  49 in total

1.  Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients.

Authors:  Hadiza S Kazaure; Sanziana A Roman; Julie A Sosa
Journal:  Ann Surg Oncol       Date:  2011-11-08       Impact factor: 5.344

2.  Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.

Authors:  Linwah Yip; Marina N Nikiforova; Sally E Carty; John H Yim; Michael T Stang; Mitchell J Tublin; Shane O Lebeau; Steven P Hodak; Jennifer B Ogilvie; Yuri E Nikiforov
Journal:  Surgery       Date:  2009-12       Impact factor: 3.982

3.  The Bethesda System for Reporting Thyroid Cytopathology.

Authors:  Edmund S Cibas; Syed Z Ali
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

4.  c-MET as a potential therapeutic target and biomarker in cancer.

Authors:  J Rafael Sierra; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

5.  BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.

Authors:  Alessandra Bommarito; Pierina Richiusa; Elvira Carissimi; Giuseppe Pizzolanti; Vito Rodolico; Giovanni Zito; Angela Criscimanna; Francesco Di Blasi; Maria Pitrone; Monica Zerilli; Marco C Amato; Gaetano Spinelli; Valeria Carina; Giuseppe Modica; M Adelfio Latteri; Aldo Galluzzo; Carla Giordano
Journal:  Endocr Relat Cancer       Date:  2011-11-14       Impact factor: 5.678

6.  TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma.

Authors:  Lesleyann Hawthorn; Leighton Stein; Ram Varma; Samuel Wiseman; Thom Loree; DongFeng Tan
Journal:  Head Neck       Date:  2004-12       Impact factor: 3.147

7.  Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.

Authors:  Veli-Matti Wasenius; Samuli Hemmer; Eeva Kettunen; Sakari Knuutila; Kaarle Franssila; Heikki Joensuu
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

8.  Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer.

Authors:  Alfredo Fusco; Gennaro Chiappetta; Pei Hui; Ginesa Garcia-Rostan; Lauren Golden; Barbara K Kinder; Deborah A Dillon; Ada Giuliano; Anna Maria Cirafici; Massimo Santoro; Juan Rosai; Giovanni Tallini
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

9.  BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.

Authors:  Cristina Romei; Raffaele Ciampi; Pinuccia Faviana; Laura Agate; Eleonora Molinaro; Valeria Bottici; Fulvio Basolo; Paolo Miccoli; Furio Pacini; Aldo Pinchera; Rossella Elisei
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

10.  c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules.

Authors:  Sara Tomei; Chiara Mazzanti; Ivo Marchetti; Leonardo Rossi; Katia Zavaglia; Francesca Lessi; Alessandro Apollo; Paolo Aretini; Giancarlo Di Coscio; Generoso Bevilacqua
Journal:  J Transl Med       Date:  2012-01-10       Impact factor: 5.531

View more
  1 in total

1.  Application of biomarkers in the diagnosis of uncertain samples of core needle biopsy of thyroid nodules.

Authors:  Yan Xiong; Xin Li; Li Liang; Dong Li; Limin Yan; Xueying Li; Jiting Di; Ting Li
Journal:  Virchows Arch       Date:  2021-07-26       Impact factor: 4.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.